HCWB 10-Q filed 2026-11-16 | Key takeaways
HCWB filed its 10-Q; the most relevant disclosure change is expanded Revenue recognition - Trimmune license: The Company recognized $6.3 million of revenue allocated to the Licensed IP at the point in time control transferred to Trimmune upon closing on March 16, 2026, and $403K of Services revenue for the nine months ended September 30, 2026; a contract liability of. Customer concentration: Trimmune (Beijing Trimmune Biotech Co. Ltd.) represented 99% of revenue.
Key takeaways
Net loss: Q3 2026 net loss of $3.2 million compared to $4.6 million in Q3 2025; nine-month 2026 net loss of $5.0 million compared to $8.7 million in the prior-year nine-month period.
Liquidity: Cash decreased to $955K at September 30, 2026 from $2.0 million at December 31, 2025; net cash used in operating activities was $8.2 million for the nine months ended September 30, 2026.
Trimmune license: The Company received $3.5 million cash (net $2.9 million after taxes) and a $3.5 million equity interest in Trimmune as the nonrefundable upfront license fee, with $6.3 million of revenue recognized for the nine months ended September 30, 2026.
Secured Notes settlement: As of October 1, 2026, the remaining outstanding Secured Notes were settled by allocating a portion of proceeds from the sale of AlloTera Therapeutics shares.
Debt financing: On November 3, 2026, the Company entered into $10 million secured debt financing ($3 million funded at closing, $7 million held as collateral); notes bear interest at 8% and 5% and mature in 24 months.
Property listing: On November 4, 2026, the Company listed its Miramar property for sale at $15 million; the property did not meet held-for-sale criteria as of September 30, 2026.
New subsidiary: On September 29, 2026, the Company formed HCWB Holdings, LLC, a Utah limited liability company; beginning with the 2026 Annual Report, the Company will present consolidated financial statements.
Key metrics
Customer concentration
Disclosure changes
- Consolidated financial statements
On September 29, 2026, the Company formed HCWB Holdings, LLC, a Utah limited liability company of which the Company is the sole member; beginning with the Annual Report for the year ended December 31, 2026, the Company will present consolidated financial statements that include the accounts of HCW Biologics Inc. and its wholly owned subsidiary.
Future financial statements will consolidate subsidiary results; $7 million of the November 2026 debt financing was deposited in the subsidiary's bank account as collateral - Revenue recognition - Trimmune license
The Company recognized $6.3 million of revenue allocated to the Licensed IP at the point in time control transferred to Trimmune upon closing on March 16, 2026, and $403K of Services revenue for the nine months ended September 30, 2026; a contract liability of $297K was reported as of September 30, 2026 representing remaining prepaid services
This is the primary revenue driver for 2026; the Company received $3.5 million cash and $3.5 million equity interest in Trimmune as upfront consideration - Debt - Secured Notes settlement
On October 1, 2026, the remaining outstanding Secured Notes (reported at $443K as of September 30, 2026) were settled by allocating a portion of the proceeds upon the sale or liquidation of AlloTera Therapeutics shares according to the provision of the Second Amendment to the Amended and Restated Note Purchase Agreement
The Secured Notes, which had been outstanding since 2024 and triggered a discretionary default by Cogent Bank due to mechanics liens, have been fully extinguished - Debt - New secured financing
On November 3, 2026, the Company entered into a $10 million secured debt financing with $3 million funded at closing and $7 million deposited as collateral; notes bear interest at 8% and 5% per annum and mature 24 months after issuance; the Company must begin paying down outstanding amounts after the six-month anniversary of closing
The Company accessed $10 million in new capital to fund operations and clinical development; the financing structure includes a collateral arrangement with the newly formed subsidiary - Property - Held for sale decision
On October 22, 2026, the Company entered a listing agreement with a real estate company to market and sell the Miramar property; on November 4, 2026, the Company listed the property for sale at an asking price of $15.0 million; the listing agreement contemplated completion of forbearance agreements with lienholders and Cogent Bank; as of September 30, 2026, the property did not meet held-for-sale criteria and continued to be classified as held-and-used
The Company is attempting to monetize its real estate asset to address outstanding liens and debt obligations; the Cogent Bank loan ($6.1 million reported as current liability) is tied to this property - Legal - Cooley LLP settlement amendment
On October 27, 2026, the Company and Cooley LLP entered an amended settlement agreement; the Company paid $10K upon signing, agreed to pay $740K by January 29, 2027 (including 8% interest) with monthly partial payments of $10K; contingent payments of up to $5.5 million remain unchanged with triggering events deemed remote; the Company reported a liability of $5.4 million for remaining legal fee amounts as of September 30, 2026
The Company continues to resolve legacy legal costs from the Arbitration; the amended terms provide a structured payment schedule while maintaining contingent payment obligations
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow HCWB in real time
Get material earnings, filing, IR, and earnings-call alerts by email.